AI assistant
Sending…
Neurogene Inc. — Director's Dealing 2014
Dec 15, 2014
33497_dirs_2014-12-15_6a38c349-a473-4820-be02-dcdaaaf713d1.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: AQUINOX PHARMACEUTICALS, INC (AQXP)
CIK: 0001404644
Period of Report: 2014-12-08
Reporting Person: Mitchell David Chilton (VP Global Regulatory & Quality)
More from Neurogene Inc.
Regulatory Filings
2026
May 12
Regulatory Filings
2026
Apr 20
Annual Report
2026
Apr 16
Proxy Solicitation & Information Statement
2026
Apr 16
Regulatory Filings
2026
Mar 24
Director's Dealing
2026
Mar 17
Director's Dealing
2026
Mar 17
Director's Dealing
2026
Mar 3
Regulatory Filings
2026
Feb 26
Director's Dealing
2026
Feb 24